The high level of plasma CHI3L1 accompanied by poor prognosis of cancer patients suggesting that CHI3L1 is a biomarker of cancer progression as well as a therapeutic target in NSCLC, PDAC and CRC. Here, CHI3L1 is linked to cancer.